Company Overview and News

 
Dhampur Sugar Mills Limited - Trading Window

2018-10-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500119 DHAMPURSUG

 
Dhampur Sugar among top bets for multibagger returns

2018-10-11 moneycontrol
In near term, the downtrend is expected to continue with persisting volatility but over a medium-term Sumit Bilgaiyan, Founder of Equity99 expects the Sensex to maintain above 33,500, he said in an interview to Moneycontrol's Sunil Shankar Matkar.
530043 ANDHRAPET 500119 ACKNIT DHAMPURSUG 500012

 
Dhampur Sugar Mills (₹142): Buy

2018-10-09 premium.thehindubusinessline
Investors with a short-term perspective can buy the stock of Dhampur Sugar Mills at current levels as the stock has rediscovered its bullish momentum.
500119 DHAMPURSUG

 
Dhampur Sugar Mills Limited - Credit Rating

2018-09-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500119 DHAMPURSUG

 
Sugar stocks jump as govt may incentivise exports

2018-09-19 thehindubusinessline
Sugar stocks jumped 5-10 per cent after Reuters reported that the government is likely to consider a proposal to get sugar mills to export 5 million tonnes of sugar by incentivising overseas sales in the 2018/19 season.
BALRAMCHIN UTTAMSUGAR 532729 500119 500038 DHAMPURSUG

 
Sugar stocks rally 20% as govt raises ethanol price

2018-09-14 thehindubusinessline
Shares of sugar companies jumped as much as 20 per cent as the government has raised the ethanol price for blending in petrol by 25 per cent.
THIRUSUGAR UTTAMSUGAR 532729 500119 507490 BANARISUG 532610 500041 DWARKESH 507450 532460 SAKHTISUG PONNIERODE RANASUG 507315 DHAMPURSUG

 
Dhampur Sugar Mills Limited - Shareholders meeting

2018-09-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500119 DHAMPURSUG

 
Intellect Design, Tata Steel, Alembic Pharma top gainers among BSE Group A stocks

2018-09-12 moneycontrol
The Indian stock market traded higher on Wednesday afternoon with the Nifty50 up 78 points while the Sensex higher by 267 points at 37,680.
ABB 500008 500119 532504 RENUKA ARJQY AMARAJABAT 533104 500470 TTST TATASTEEL 532670 TATLY 500002 NAVINFLUOR ABBDY GLOBUSSPR DHAMPURSUG

 
Industry wants sugar price fixed at ₹36/kg

2018-09-05 thehindubusinessline
The sugar industry has appealed to the Union government to increase the minimum selling price of sugar to ₹36/kg as it anticipates the total surplus in sugar production to go up to 19 million tonnes (mt) by next year.
500119 DHAMPURSUG

 
Dhampur Sugar Mills Limited - Shareholders meeting

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500119 DHAMPURSUG

 
Dhampur Sugar Mills Limited - Investor Presentation

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500119 DHAMPURSUG

 
Dhampur Sugar Mills slips 3% on poor Q1 numbers

2018-08-08 moneycontrol
Shares of Dhampur Sugar Mills fell 3.6 percent intraday Wednesday on the back of poor June quarter (Q1FY19) numbers.
500119 DHAMPURSUG

 
Dhampur Sugar Mills Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500119 DHAMPURSUG

 
Dhampur Sugar Mills Limited - AGM/Book Closure

2018-08-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500119 DHAMPURSUG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...